Pharsight

Dovato generic

Dovato is an antiviral drug used in the treatment of HIV infection. It contains active ingredients Dolutegravir Sodium and Lamivudine. It is owned by ViiV Healthcare and was first authorized for market use on April 8, 2019. Dovato has a total of 5 drug patents, none of which have expired yet.

When will Dovato generic be available?

The generic version of Dovato is expected to be released after January 24, 2031. This is based on the expiration date of its last patent - US11234985 titled 'Antiviral therapy', expiring on January 24, 2031.

Dovato uses

Dovato is primarily used to treat HIV infection. The drug's active ingredients, Dolutegravir Sodium and Lamivudine, work conjointly to inhibit the growth of the virus in the human body, helping to manage the disease effectively.

Dovato patent expiration

Dovato holds a total of 5 patents, with the last patent, US11234985 titled 'Antiviral therapy', set to expire on January 24, 2031. This will also mark the earliest possible release date for Dovato generic. Below are the details of the patent:

EPO Oppostions filed on Dovato

Dovato dosage

Want to ask something?